CFChristoffer Flensburg

Christoffer Flensburg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christoffer Flensburg has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hypoactive APOBEC3A Achieves High-Level Mutagenesis and Drives Squamous Cell Carcinoma.

    by Zhen Xu, Christoffer Flensburg, Lorraine A. O'REilly, Rebecca A. Bilardi, Lachlan W. Whitehead, Danielle K. Chen, Andrew Kueh, Kate D. Sutherland, Ian J. Majewski

    APOBEC proteins shape the somatic mutation spectrum of many cancers by binding and editing DNA. Modeling APOBEC-induced changes in cancer has been challenging due to the toxicity of these enzymes. Here, we overcame this barrier using a mutant form of APOBEC3A with impaired deaminase activity by changing arginine 128 to alanine (A3AR128A). Overexpressing A3AR128A in murine epithelium induced squamous cell carcinoma (SCC) in the skin, head and neck region, and cervix, mirroring the human disease spectrum. Tumor formation was further accelerated by concomitant Trp53 loss. A3AR128A cancers carried frequent alterations in the NOTCH and RAS-PI3K pathways, and recurrent mutations in genes encoding histone H3 were also observed. Cross-species analysis revealed how APOBEC accessibility influences cancer driver gene selection. A catalogue of 235,790 mutations was used to refine mutational signatures linked to A3A. These results shed light on how DNA damage from A3A contributes to tumorigenesis.

  • Open Access

    Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

    by Piers Blombery, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, et al.

  • Open Access

    Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition

    by Hesham D. Abdulla, Raed Alserihi, Christoffer Flensburg, Waruni Abeysekera, Meng-Xiao Luo, Daniel H.D. Gray, Xiaodong Liu, Gordon K. Smyth, Warren S. Alexander, Ian J. Majewski, et al.

    Cell competition has recently emerged as an important tumor suppressor mechanism in the thymus that inhibits autonomous thymic maintenance. Here, we show that the oncogenic transcription factor Lmo2 causes autonomous thymic maintenance in transgenic mice by inhibiting early T cell differentiation. This autonomous thymic maintenance results in the development of self-renewing preleukemic stem cells (pre-LSCs) and subsequent leukemogenesis, both of which are profoundly inhibited by restoration of thymic competition or expression of the antiapoptotic factor BCL2. Genomic analyses revealed the presence of Notch1 mutations in pre-LSCs before subsequent loss of tumor suppressors promotes the transition to overt leukemogenesis. These studies demonstrate a critical role for impaired cell competition in the development of pre-LSCs in a transgenic mouse model of T cell acute lymphoblastic leukemia (T-ALL), implying that this process plays a role in the ontogeny of human T-ALL.


  • Detecting copy number alterations in RNA-Seq using SuperFreq

    by Christoffer Flensburg, Alicia Oshlack, Ian J Majewski

    Calling copy number alterations (CNAs) from RNA sequencing (RNA-Seq) is challenging, because of the marked variability in coverage across genes and paucity of single nucleotide polymorphisms (SNPs). We have adapted SuperFreq to call absolute and allele sensitive CNAs from RNA-Seq. SuperFreq uses an error-propagation framework to combine and maximize information from read counts and B-allele frequencies. We used datasets from The Cancer Genome Atlas (TCGA) to assess the validity of CNA calls from RNA-Seq. When ploidy estimates were consistent, we found agreement with DNA SNP-arrays for over 98% of the genome for acute myeloid leukaemia (TCGA-AML, n = 116) and 87% for colorectal cancer (TCGA-CRC, n = 377). The sensitivity of CNA calling from RNA-Seq was dependent on gene density. Using RNA-Seq, SuperFreq detected 78% of CNA calls covering 100 or more genes with a precision of 94%. Recall dropped for focal events, but this also depended on signal intensity. For example, in the CRC cohort SuperFreq identified all cases (7/7) with high-level amplification of ERBB2, where the copy number was typically >20, but identified only 6% of cases (1/17) with moderate amplification of IGF2, which occurs over a smaller interval. SuperFreq offers an integrated platform for identification of CNAs and point mutations. As evidence of how SuperFreq can be applied, we used it to reproduce the established relationship between somatic mutation load and CNA profile in CRC using RNA-Seq alone. SuperFreq is implemented in R and the code is available through GitHub: https://github.com/ChristofferFlensburg/SuperFreq/. Data and code to reproduce the figures are available at: https://gitlab.wehi.edu.au/flensburg.c/SuperFreq_RNA_paper. Data from TCGA (phs000178) was accessed from GDC following completion of a data access request through the database of Genotypes and Phenotypes (dbGaP). Data from the Leucegene consortium was downloaded from GEO (AML samples: GSE67040; normal CD34+ cells: GSE48846). Supplementary data are available at Bioinformatics online.


  • Open Access

    Detecting copy number alterations in RNA-Seq using SuperFreq

    by Christoffer Flensburg, Alicia Oshlack, Ian J. Majewski

    Calling copy number alterations (CNAs) from RNA-Seq is challenging, because differences in gene expression mean that read depth across genes varies by several orders of magnitude and there is a paucity of informative single nucleotide polymorphisms (SNPs). We previously developed SuperFreq to analyse exome data of tumours by combining variant calling and copy number estimation in an integrated pipeline. Here we have used the SuperFreq framework for the analysis of RNA sequencing (RNA-Seq) data, which allows for the detection of absolute and allele sensitive CNAs. SuperFreq uses an error-propagation framework to combine and maximise the information available in the read depth and B-allele frequencies of SNPs (BAFs) to make CNA calls on RNA-seq data. We used data from The Cancer Genome Atlas (TCGA) to evaluate the CNA called from RNA-Seq with those generated from SNP-arrays. When ploidy estimates were consistent, we found excellent agreement with CNAs called from DNA of over 98% of the genome for acute myeloid leukaemia (TCGA-AML, n=116) and 87% for colorectal cancer (TCGA-CRC, n=377), which has a much higher CNA burden. As expected, the sensitivity of CNA calling from RNA-Seq was dependent on gene density. Nonetheless, using RNA-Seq SuperFreq detected 78% of CNA calls covering 100 or more genes with a precision of 94%. Recall dropped markedly for focal events, but this also depended on the signal intensity. For example, in the CRC cohort SuperFreq identified 100% (7/7) of cases with high-level amplification of ERBB2, where the copy number was typically >20, but identified only 6% (1/17) of cases with moderate amplification of IGF2, typically 4 or 5 copies over a smaller region (median 5 flanking genes for IGF2, compared to 20 for ERBB2). We were able to reproduce the relationship between mutational load and CNA profile in CRC using RNA-Seq alone. SuperFreq offers an integrated platform for identification of CNAs and point mutations from RNA-seq in cancer transcriptomes. The software is implemented in R and is available through GitHub: https://github.com/ChristofferFlensburg/SuperFreq .


  • Open Access

    SuperFreq: Integrated mutation detection and clonal tracking in cancer

    by Christoffer Flensburg, Tobias Sargeant, Alicia Oshlack, Ian J. Majewski

    Analysing multiple cancer samples from an individual patient can provide insight into the way the disease evolves. Monitoring the expansion and contraction of distinct clones helps to reveal the mutations that initiate the disease and those that drive progression. Existing approaches for clonal tracking from sequencing data typically require the user to combine multiple tools that are not purpose-built for this task. Furthermore, most methods require a matched normal (non-tumour) sample, which limits the scope of application. We developed SuperFreq, a cancer exome sequencing analysis pipeline that integrates identification of somatic single nucleotide variants (SNVs) and copy number alterations (CNAs) and clonal tracking for both. SuperFreq does not require a matched normal and instead relies on unrelated controls. When analysing multiple samples from a single patient, SuperFreq cross checks variant calls to improve clonal tracking, which helps to separate somatic from germline variants, and to resolve overlapping CNA calls. To demonstrate our software we analysed 304 cancer-normal exome samples across 33 cancer types in The Cancer Genome Atlas (TCGA) and evaluated the quality of the SNV and CNA calls. We simulated clonal evolution through in silico mixing of cancer and normal samples in known proportion. We found that SuperFreq identified 93% of clones with a cellular fraction of at least 50% and mutations were assigned to the correct clone with high recall and precision. In addition, SuperFreq maintained a similar level of performance for most aspects of the analysis when run without a matched normal. SuperFreq is highly versatile and can be applied in many different experimental settings for the analysis of exomes and other capture libraries. We demonstrate an application of SuperFreq to leukaemia patients with diagnosis and relapse samples. Cancer is a disease that continues to evolve. Understanding how it changes can provide key biological insights; for example, it can help to identify recurrent patterns associated with therapy resistance. However, tracking clonal evolution in a cancer from sequencing data is a major analytical challenge. We have developed SuperFreq, an analysis framework purpose built for the detection of intra-tumoural heterogeneity and clonal evolution. SuperFreq encapsulates mutation detection, quality assessment, clonal tracking and phylogeny, for both point mutations and copy number alterations. To demonstrate the major advance that SuperFreq offers, we developed a test dataset with engineered clones, made by blending data from cancer and normal samples from The Cancer Genome Atlas. We demonstrate that SuperFreq exhibits robust performance, both for detecting clones and for assigning mutations to clones. SuperFreq is a powerful and adaptable analysis framework that can be applied to address many research questions. We include an example application, where we identify both early and relapse-specific driver mutations in an acute myeloid leukaemia.


  • Open Access

    Finding a suitable library size to call variants in RNA-seq

    by Anna Quaglieri, Christoffer Flensburg, Terence P Speed, Ian J Majewski

    Background: RNA-Seq allows the study of both gene expression changes and transcribed mutations, providing a highly effective way to gain insight into cancer biology. When planning the sequencing of a large cohort of samples, library size is a fundamental factor affecting both the overall cost and the quality of the results. While several studies analyse the effect that library size has on differential expression analyses, sensitivity analysis for variant detection has received far less attention. Results: We simulated shallower sequencing depths by downsampling 45 AML samples that are part of the Leucegene project, which were originally sequenced at high depth. We compared the sensitivity of six methods of recovering validated mutations on the same samples. The methods compared are a combination of three popular callers (MuTect, VarScan, and VarDict) and two filtering strategies. We observed an incremental loss in sensitivity when simulating libraries of 80M, 50M, 40M, 30M and 20M fragments, with the largest loss detected with less than 30M fragments (below 90%). The sensitivity in recovering indels varied markedly between callers, with VarDict showing the highest sensitivity (60%). Single nucleotide variant sensitivity is relatively consistent across methods, apart from MuTect, whose default filters need adjustment when using RNA-Seq. We also analysed 136 RNA-Seq samples from the TCGA-LAML cohort, assessing the change in sensitivity between the initial libraries (average 59M fragments) and after downsampling to 40M fragments. When considering single nucleotide variants in recurrently mutated myeloid genes we found a comparable performance, with a 3% average loss in sensitivity using 40M fragments. Conclusions: Between 30M and 40M fragments are needed to recover 90%-95% of the initial variants on recurrently mutated myeloid genes. To extend this result to another cancer type, an exploration of the characteristics of its mutations and gene expression patterns is suggested.

  • Open Access

    SuperFreq: Integrated mutation detection and clonal tracking in cancer

    by Christoffer Flensburg, Tobias Sargeant, Alicia Oshlack, Ian Majewski

    Analysing multiple cancer samples from an individual patient can provide insight into the way the disease evolves. Monitoring the expansion and contraction of distinct clones helps to reveal the mutations that initiate the disease and those that drive progression. Existing approaches for clonal tracking from sequencing data typically require the user to combine multiple tools that are not purpose-built for this task. Furthermore, most methods require a matched normal (non-tumour) sample, which limits the scope of application. We developed SuperFreq, a cancer exome sequencing analysis pipeline that integrates identification of somatic single nucleotide variants (SNVs) and copy number alterations (CNAs) and clonal tracking for both. SuperFreq does not require a matched normal and instead relies on unrelated controls. When analysing multiple samples from a single patient, SuperFreq cross checks variant calls to improve clonal tracking, which helps to separate somatic from germline variants, and to resolve overlapping CNA calls. To demonstrate our software we analysed 304 cancer-normal exome samples across 33 cancer types in The Cancer Genome Atlas (TCGA) and evaluated the quality of the SNV and CNA calls. We simulated clonal evolution through in silico mixing of cancer and normal samples in known proportion. We found that SuperFreq identified 93% of clones with a cellular fraction of at least 50% and mutations were assigned to the correct clone with high recall and precision. In addition, SuperFreq maintained a similar level of performance for most aspects of the analysis when run without a matched normal. SuperFreq is highly versatile and can be applied in many different experimental settings for the analysis of exomes and other capture libraries. We demonstrate an application of SuperFreq to leukaemia patients with diagnosis and relapse samples. SuperFreq is implemented in R and available on github at https://github.com/ChristofferFlensburg/SuperFreq .


  • Exclusive final states in diffractive excitation

    by Christoffer Flensburg, Gösta Gustafson, Leif Lönnblad


  • Open Access

    Exclusive final states in diffractive excitation

    by Christoffer Flensburg, Gosta Gustafson, Leif Lonnblad

    In this paper we describe a formalism for generating exclusive final states in diffractive excitation, based on the optical analogy where diffraction is fully determined by the absorption into inelastic channels. The formalism is based on the Good--Walker formalism for diffractive excitation, and it is assumed that the virtual parton cascades represent the diffractive eigenstates defined by a definite absorption amplitude. We emphasize that, although diffractive excitation is basically a quantum-mechanical phenomenon with strong interference effects, it is possible to calculate the different interfering components to the amplitude in an event generator, add them and thus calculate the reaction cross section for exclusive diffractive final states. The formalism is implemented in the DIPSY event generator, introducing no tunable parameters beyond what has been determined previously in studies of non-diffractive events. Some early results from DIS and proton-proton collisions are presented, and compared to experimental data.